Literature DB >> 24294285

Comparison of late HIV diagnosis as a marker of care for Aboriginal versus non-Aboriginal people living with HIV in Ontario.

Denise Jaworsky1, Laverne Monette, Janet Raboud, Doe O'Brien-Teengs, Christina Diong, Sandra Blitz, Sean B Rourke, Mona R Loutfy.   

Abstract

BACKGROUND: Studies have found that Aboriginal people living with HIV/AIDS (APHAs) are more likely than non-APHAs to receive suboptimal HIV care, yet achieve similar clinical outcomes with proper care.
OBJECTIVE: To compare the proportions of individuals diagnosed late with HIV between APHAs and non-APHAs within the Ontario HIV Treatment Network Cohort Study (OCS).
METHODS: The analysis included OCS participants who completed the baseline visit by November 2009. Two definitions of the outcome of late HIV diagnosis were used: the proportion of participants with an AIDS-defining illness (ADI) before or within three months of HIV diagnosis; and the proportion of participants with a CD4(+) count <200 cells/mL at diagnosis. Logistic regression analysis was used to assess the association between Aboriginal ethnicity and late HIV diagnosis.
RESULTS: APHAs were more likely to be female and have lower income, education and employment. No statistically significant differences were noted in the proportions receiving a late HIV diagnosis defined by ADI (Aboriginal 5.2% versus non-Aboriginal 6.3%; P=0.40). Multivariate logistic regression analysis revealed a significant association between Aboriginal ethnicity and late HIV diagnosis defined by CD4(+) count after adjusting for age and HIV risk factor (OR 1.55; P=0.04). DISCUSSION: APHAs were more likely to have a CD4(+) count <200 cells/mL at diagnosis but had similar clinical outcomes from late diagnosis when defined by ADI. However, differences may be underestimated due to recruitment limitations and selection bias.
CONCLUSION: Additional work is needed to address the socioeconomic and health care needs of APHAs.

Entities:  

Keywords:  Aboriginal peoples; Access to care; Cohort study; HIV; HIV diagnosis; Quality of care

Year:  2012        PMID: 24294285      PMCID: PMC3597406          DOI: 10.1155/2012/930289

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  33 in total

1.  Markers of access to and quality of primary care for aboriginal people in Ontario, Canada.

Authors:  Baiju R Shah; Nadia Gunraj; Janet E Hux
Journal:  Am J Public Health       Date:  2003-05       Impact factor: 9.308

Review 2.  HIV treatment as prevention among injection drug users.

Authors:  Evan Wood; Michael John Milloy; Julio S G Montaner
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

3.  "You need to know where we're coming from": Canadian Aboriginal women's perspectives on culturally appropriate HIV counseling and testing.

Authors:  Dawn Bucharski; Linda I Reutter; Linda D Ogilvie
Journal:  Health Care Women Int       Date:  2006-09

4.  Rapid point-of-care HIV testing in community-based anonymous testing program: a valuable alternative to conventional testing.

Authors:  D Guenter; J Greer; A Barbara; G Robinson; J Roberts; G Browne
Journal:  AIDS Patient Care STDS       Date:  2008-03       Impact factor: 5.078

5.  Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS.

Authors:  Sandra Schwarcz; Ling Hsu; James W Dilley; Lisa Loeb; Kimberly Nelson; Stephen Boyd
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

6.  Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group.

Authors:  A B Bindman; D Osmond; F M Hecht; J S Lehman; K Vranizan; D Keane; A Reingold
Journal:  JAMA       Date:  1998-10-28       Impact factor: 56.272

7.  Voluntary counselling and testing uptake and HIV prevalence among tuberculosis patients in Jogjakarta, Indonesia.

Authors:  Yodi Mahendradhata; Riris A Ahmad; Theodorus A Kusuma; Marleen Boelaert; Marieke J Van der Werf; Michael E Kimerling; Patrick Van der Stuyft
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-06-20       Impact factor: 2.184

8.  Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver.

Authors:  Kevin J P Craib; Patricia M Spittal; Evan Wood; Nancy Laliberte; Robert S Hogg; Kathy Li; Katherine Heath; Mark W Tyndall; Michael V O'Shaughnessy; Martin T Schechter
Journal:  CMAJ       Date:  2003-01-07       Impact factor: 8.262

9.  The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection.

Authors:  H B Krentz; M C Auld; M J Gill
Journal:  HIV Med       Date:  2004-03       Impact factor: 3.180

10.  Predictors of delayed HIV diagnosis in a recently diagnosed cohort.

Authors:  Jennifer K Mayben; Jennifer R Kramer; Michael A Kallen; Luisa Franzini; David R Lairson; Thomas P Giordano
Journal:  AIDS Patient Care STDS       Date:  2007-03       Impact factor: 5.078

View more
  3 in total

Review 1.  HIV Among Indigenous peoples: A Review of the Literature on HIV-Related Behaviour Since the Beginning of the Epidemic.

Authors:  Joel Negin; Clive Aspin; Thomas Gadsden; Charlotte Reading
Journal:  AIDS Behav       Date:  2015-09

2.  Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care.

Authors:  Angela Cescon; Sophie Patterson; Colin Davey; Erin Ding; Janet M Raboud; Keith Chan; Mona R Loutfy; Curtis Cooper; Ann N Burchell; Alexis K Palmer; Christos Tsoukas; Nima Machouf; Marina B Klein; Sean B Rourke; Anita Rachlis; Robert S Hogg; Julio S G Montaner
Journal:  J Int AIDS Soc       Date:  2015-10-05       Impact factor: 5.396

3.  Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting.

Authors:  M-J Milloy; Alexandra King; Thomas Kerr; Evan Adams; Hasina Samji; Silvia Guillemi; Evan Wood; Julio Montaner
Journal:  J Int AIDS Soc       Date:  2016-04-18       Impact factor: 5.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.